---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000054"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:34:20.788365+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones

## Summary
- Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.
- Viatris pays $25M upfront; Lexicon eligible for up to $12M regulatory and $185M sales milestones.
- Tiered royalties: low double-digit to upper-teens percentages of net sales in licensed territory.
- Lexicon to supply drug under a separate manufacturing and supply agreement with Viatris.
- Viatris responsible for regulatory approvals, commercialization, and any additional clinical trials.

## SEC filing metadata
- accession: 0001062822-24-000054
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/0001062822-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000054/lxrx-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000054
- JSON: https://secwatch.observer/filing/0001062822-24-000054.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.